Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Sep;62(3):430–435. doi: 10.1038/bjc.1990.312

Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression.

E May 1, H Mouriesse 1, F May-Levin 1, J F Qian 1, P May 1, J C Delarue 1
PMCID: PMC1971463  PMID: 1976381

Abstract

We recently defined a new early prognostic factor, the ER+(R) status, which permits the discrimination of a group presenting a high risk of early relapse among the ER+ patients. This group was referred to as ER+(R2) in contrast to ER+(R1) which corresponded to the group of ER+ patients having a lower risk of early relapse. Taking into account the whole population including the ER- and inflammatory tumours, we have extended this view and showed that ER+(R) status is a significant predictor of disease-free survival. Determination of c-erbB-2 mRNA levels in the same series of tumours showed that high expression of c-erbB-2 mRNA is significantly correlated with ER-, inflammatory tumours and with lymph nodes involvement. Moreover, a multivariate analysis showed that c-erbB-2 mRNA overexpression was a significant predictor of early relapse (P = 0.02), as significant as ER negativity and ER+(R2). For ER+ patients a high level of c-erbB-2 mRNA constitutes a higher risk of relapse for both ER+(R1) and ER+(R2) patients. However, in the case of ER- patients, early relapses were strongly correlated with c-erbB-2 overexpression. The counterpart of this observation is that ER- patients with no overexpression of c-erbB-2 constitute a group with a relatively good prognosis.

Full text

PDF
430

Images in this article

432Figure 1
on p.432

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aamdal S., Børmer O., Jørgensen O., Høst H., Eliassen G., Kaalhus O., Pihl A. Estrogen receptors and long-term prognosis in breast cancer. Cancer. 1984 Jun 1;53(11):2525–2529. doi: 10.1002/1097-0142(19840601)53:11<2525::aid-cncr2820531126>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  2. Allegra J. C., Lippman M. E., Simon R., Thompson E. B., Barlock A., Green L., Huff K. K., Do H. M., Aitken S. C., Warren R. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep. 1979 Aug;63(8):1271–1277. [PubMed] [Google Scholar]
  3. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bargmann C. I., Hung M. C., Weinberg R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986 Jan 16;319(6050):226–230. doi: 10.1038/319226a0. [DOI] [PubMed] [Google Scholar]
  5. Barnes D. M., Lammie G. A., Millis R. R., Gullick W. L., Allen D. S., Altman D. G. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer. 1988 Oct;58(4):448–452. doi: 10.1038/bjc.1988.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Berger M. S., Locher G. W., Saurer S., Gullick W. J., Waterfield M. D., Groner B., Hynes N. E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988 Mar 1;48(5):1238–1243. [PubMed] [Google Scholar]
  7. Blanco G., Alavaikko M., Ojala A., Collan Y., Heikkinen M., Hietanen T., Aine R., Taskinen P. J. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients. Anticancer Res. 1984 Nov-Dec;4(6):383–389. [PubMed] [Google Scholar]
  8. Clark G. M., McGuire W. L., Hubay C. A., Pearson O. H., Marshall J. S. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med. 1983 Dec 1;309(22):1343–1347. doi: 10.1056/nejm198312013092240. [DOI] [PubMed] [Google Scholar]
  9. Contesso G., Rouessé J., Genin J. L'envahissement ganglionnaire loco-régional des cancers du sein. Bull Cancer. 1975 Oct-Dec;62(4):359–372. [PubMed] [Google Scholar]
  10. Coussens L., Yang-Feng T. L., Liao Y. C., Chen E., Gray A., McGrath J., Seeburg P. H., Libermann T. A., Schlessinger J., Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985 Dec 6;230(4730):1132–1139. doi: 10.1126/science.2999974. [DOI] [PubMed] [Google Scholar]
  11. Feldman J. G., Pertschuk L. P., Carter A. C., Eisenberg K. B., Fleisher J. Histochemical estrogen binding. An independent predictor of recurrence and survival in stage II breast cancer. Cancer. 1986 Mar 1;57(5):911–916. doi: 10.1002/1097-0142(19860301)57:5<911::aid-cncr2820570505>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  12. Fisher B., Redmond C. K., Wickerham D. L., Rockette H. E., Brown A., Allegra J., Bowman D., Plotkin D., Wolter J. Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res Treat. 1983;3(4):355–364. doi: 10.1007/BF01807588. [DOI] [PubMed] [Google Scholar]
  13. Glisin V., Crkvenjakov R., Byus C. Ribonucleic acid isolated by cesium chloride centrifugation. Biochemistry. 1974 Jun 4;13(12):2633–2637. doi: 10.1021/bi00709a025. [DOI] [PubMed] [Google Scholar]
  14. Guérin M., Barrois M., Terrier M. J., Spielmann M., Riou G. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988;3(1):21–31. [PubMed] [Google Scholar]
  15. Guérin M., Gabillot M., Mathieu M. C., Travagli J. P., Spielmann M., Andrieu N., Riou G. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989 Feb 15;43(2):201–208. doi: 10.1002/ijc.2910430205. [DOI] [PubMed] [Google Scholar]
  16. Howell A., Barnes D. M., Harland R. N., Redford J., Bramwell V. H., Wilkinson M. J., Swindell R., Crowther D., Sellwood R. A. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984 Mar 17;1(8377):588–591. doi: 10.1016/s0140-6736(84)90995-4. [DOI] [PubMed] [Google Scholar]
  17. Hähnel R., Woodings T., Vivian A. B. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979 Aug;44(2):671–675. doi: 10.1002/1097-0142(197908)44:2<671::aid-cncr2820440238>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  18. Knight W. A., Livingston R. B., Gregory E. J., McGuire W. L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed] [Google Scholar]
  19. Kraus M. H., Popescu N. C., Amsbaugh S. C., King C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 1987 Mar;6(3):605–610. doi: 10.1002/j.1460-2075.1987.tb04797.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lacroix H., Iglehart J. D., Skinner M. A., Kraus M. H. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene. 1989 Feb;4(2):145–151. [PubMed] [Google Scholar]
  21. May E., Mouriesse H., May-Levin F., Contesso G., Delarue J. C. A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. Oncogene. 1989 Aug;4(8):1037–1042. [PubMed] [Google Scholar]
  22. Parl F. F., Schmidt B. P., Dupont W. D., Wagner R. K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer. 1984 Nov 15;54(10):2237–2242. doi: 10.1002/1097-0142(19841115)54:10<2237::aid-cncr2820541029>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  23. Pichon M. F., Pallud C., Brunet M., Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 1980 Sep;40(9):3357–3360. [PubMed] [Google Scholar]
  24. Saez S., Cheix F., Asselain B. Prognostic value of estrogen and progesterone receptors in primary breast cancer. Breast Cancer Res Treat. 1983;3(4):345–353. doi: 10.1007/BF01807587. [DOI] [PubMed] [Google Scholar]
  25. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  26. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. doi: 10.1126/science.2470152. [DOI] [PubMed] [Google Scholar]
  27. Tandon A. K., Clark G. M., Chamness G. C., Ullrich A., McGuire W. L. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989 Aug;7(8):1120–1128. doi: 10.1200/JCO.1989.7.8.1120. [DOI] [PubMed] [Google Scholar]
  28. Varley J. M., Swallow J. E., Brammar W. J., Whittaker J. L., Walker R. A. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. 1987;1(4):423–430. [PubMed] [Google Scholar]
  29. Venter D. J., Tuzi N. L., Kumar S., Gullick W. J. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet. 1987 Jul 11;2(8550):69–72. doi: 10.1016/s0140-6736(87)92736-x. [DOI] [PubMed] [Google Scholar]
  30. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]
  31. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986 Jan 16;319(6050):230–234. doi: 10.1038/319230a0. [DOI] [PubMed] [Google Scholar]
  32. Zeillinger R., Kury F., Czerwenka K., Kubista E., Sliutz G., Knogler W., Huber J., Zielinski C., Reiner G., Jakesz R. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 1989 Jan;4(1):109–114. [PubMed] [Google Scholar]
  33. Zhou D. J., Ahuja H., Cline M. J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene. 1989 Jan;4(1):105–108. [PubMed] [Google Scholar]
  34. van de Vijver M. J., Peterse J. L., Mooi W. J., Wisman P., Lomans J., Dalesio O., Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988 Nov 10;319(19):1239–1245. doi: 10.1056/NEJM198811103191902. [DOI] [PubMed] [Google Scholar]
  35. van de Vijver M., van de Bersselaar R., Devilee P., Cornelisse C., Peterse J., Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987 May;7(5):2019–2023. doi: 10.1128/mcb.7.5.2019-2023.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES